EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

NanoReady: A ready-made DC-selective delivery platform for personalized mRNA cancer vaccines with strong NHP immunogenicity

Sojin Lee, Soyoung Kim, Sooyeon Kim, Kyujin Kyung, Goeun Kim, Jeongpyo Nam, Jaeah Lee, Seungwei Jeong, Gunhee Seo, Helen Cho

Journal of Controlled Release · 2026

DOI: 10.1016/j.jconrel.2026.115176 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2026. Verfasst von Sojin Lee und 9 weiteren Autor:innen. Beteiligte Einrichtung: R&D Center, Samyang Biopharm Corporation, Pangyo, South Korea. Hauptthemen laut MEDLINE: Cancer Vaccines, Dendritic Cells, RNA, Messenger, Nanoparticles. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

NanoReady is a next-generation mRNA delivery platform designed to overcome the limitations of conventional lipid-based systems, such as lipid nanoparticles (LNP) and Lipoplex (LPX), particularly for personalized cancer vaccines. It combines a novel cationic lipid with a biodegradable polymer, forming a stable nanoparticle that efficiently encapsulates mRNAs with a wide range of lengths. NanoReady nanoparticles can be pre-assembled without RNA as a ready-made formulation, and upon availability of patient-specific antigen-encoding mRNA, NanoReady rapidly incorporates the RNA to form uniform, administration-ready particles. NanoReady selectively delivers antigen mRNA to professional antigen-presenting cells, particularly dendritic cells in the spleen, where robust antigen-specific T-cell responses are elicited. When combined with mRNA, NanoReady forms multilamellar nanoparticles that exhibit high mRNA loading capacity and efficient endosomal release, leading to enhanced protein expression. As a result, it induces strong T-cell immune responses to the encoding antigen that overcomes immune tolerance when encoding self-antigens. In B16-F10 tumor mouse model, NanoReady mRNA vaccine encoding the self-antigen mTRP2 induced potent CD8 T-cell responses, resulting in significant tumor growth suppression and improved survival. Compared to DOTMA based LPX formulations, NanoReady achieved markedly higher antigen expression, stronger antigen-specific T cell immunogenicity, and superior anti-tumor efficacy. Importantly, a pilot non-human primate (NHP) study demonstrated antigen-specific T-cell immunogenicity following NanoReady-mRNA vaccination, supporting translational potential. Furthermore, repeated administration of NanoReady-mRNA vaccine showed no toxicity in various animal models confirming the platform's high biocompatibility and safety. These findings highlight NanoReady as a promising platform for personalized cancer vaccines, combining high mRNA delivery efficiency, robust immune response, and excellent safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesDendritic CellsRNA, MessengerNanoparticlesmRNA VaccinesAnimalsMice, Inbred C57BLFemaleHumansMelanoma, ExperimentalLipidsNanovaccinesPrecision MedicineAntigens, Neoplasm

Stichwörter der Autor:innen

Ready-made delivery platformRobust CD8(+) T-cell responsesSplenic dendritic cell deliverymRNA loading capacitymRNA personalized cancer vaccine

Substanzen

Cancer VaccinesRNA, MessengermRNA VaccinesLipidsNanovaccinesAntigens, Neoplasm

Autor:innen und Institutionen

  • R&D Center, Samyang Biopharm Corporation, Pangyo, South Korea.
  • CQC, Samyang Biopharm Corporation, Pangyo, South Korea.
  • R&D Center, Samyang Biopharm Corporation, Pangyo, South Korea. Electronic address: helen.cho@samyang.com.

Zitieren

APA

Lee, S., Kim, S., Kim, S., Kyung, K., Kim, G., Nam, J., Lee, J., Jeong, S., Seo, G., & Cho, H. (2026). NanoReady: A ready-made DC-selective delivery platform for personalized mRNA cancer vaccines with strong NHP immunogenicity. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2026.115176

Vancouver

Lee S, Kim S, Kim S, Kyung K, Kim G, Nam J, et al. NanoReady: A ready-made DC-selective delivery platform for personalized mRNA cancer vaccines with strong NHP immunogenicity. Journal of Controlled Release. 2026. doi:10.1016/j.jconrel.2026.115176

BibTeX
@article{Lee2026,
  author = {Lee, Sojin and Kim, Soyoung and Kim, Sooyeon and Kyung, Kyujin and Kim, Goeun and Nam, Jeongpyo and Lee, Jaeah and Jeong, Seungwei and Seo, Gunhee and Cho, Helen},
  title = {NanoReady: A ready-made DC-selective delivery platform for personalized mRNA cancer vaccines with strong NHP immunogenicity},
  journal = {Journal of Controlled Release},
  year = {2026},
  doi = {10.1016/j.jconrel.2026.115176}
}
Kostenlos starten →